Novel classes of antibiotics or more of the same?

British Journal of Pharmacology

Volumn 163, Issue 1, 2011, Pages 184-194

  Coates, Anthony Rm ^a   Halls, Gerry ^b   Hu, Yanmin ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Medical Marketing Services   (United Kingdom)

Author keywords

antibiotic resistance; bacterial infections; bacteriophages; genomics; multiplying bacteria; non culturable bacteria; non multiplying bacteria; novel antibiotics

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BAL 30072; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFTAROLINE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CETHROMYCIN; CLAVULANIC ACID; DALBAVANCIN; DELAFLOXACIN; DRUG ANALOG; FINAFLOXACIN; GSK 1322322; ICLAPRIM; MEROPENEM; MODITHROMYCIN; ORITAVANCIN; OXA 48; PENICILLIN DERIVATIVE; PLEUROMUTILIN; QUINOLONE DERIVATIVE; RADEZOLID; SIDEROPHORE; SOLITHROMYCIN; TD 1792; TELAVANCIN; TOREZOLID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; CHEMICAL STRUCTURE; DRUG ACTIVITY; DRUG CONTROL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; GRAM NEGATIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; VETERINARY MEDICINE;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 79953710021     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01250.x     Document Type: Review

References (49)

1. Andersson DI, (2006). The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 9: 461-465. (Pubitemid 44397630)
2. Bax RP, Anderson R, Crew J, Fletcher P, Johnson T, Kaplan E, et al,. (1998). Antibiotic resistance-what can we do? Nat Med 4: 545-546.
3. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, et al,. (2010). Type 11A topoisomerase inhibition by a new class of antibacterial agents. Nature 19: 935-940.
4. Becker D, Selbach M, Rollenhagen C, Ballmaier M, Meyer TF, Mann M, et al,. (2006). Robust salmonella metabolism limits possibilities for new antimicrobials. Nature 16: 303-307.
5. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al,. (2009). Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1-12.
6. Brogden RN, Carmine A, Heel RC, Morley PA, Speight TM, Avery GS, (1981). Combination clavulanic acid. Drugs 22: 337-362.
7. Brotz-Oesterhelt H, Sass P, (2010). Postgenomic stategies in antibacterial drug discovery. Future Microbiol 5: 1553-1579.
8. Butler MS, Buss AD, (2006). Natural products-the future scaffolds for novel antibiotics? Biochem Pharmacol 71: 919-929.
9. Chambers HF, Deleo FR, (2009). Resistance Staph aureus to penicillin and methicillin. Nat Rev Microbiol 7: 629-641.
10. van Cleef BA, Verkade EJ, Wulf MW, Buiting AG, Voss A, Huijsdens XW, et al,. (2010). Prevalence of livestock-associated MRSA in communities with high pig-densities in the Netherlands. PLoS ONE 5: e9385.
11. Coates AR, Hu Y, (2008). Targeting non-multiplying organisms as a way to develop novel antimicrobials. Trends Pharmacol Sci 29: 143-150.
12. Coates A, Hu Y, Bax R, Page C, (2002). The future challenges facing the development of new antimicrobial drugs. Nature Rev Drug Discovery 1: 895-910. (Pubitemid 37361584)
13. CMR International (2009). Available at (accessed February 2011).
14. Da Re S, Garnier F, Guerin E, Campoy S, Denis F, Ploy MC, (2009). The SOS response promotes qnrB quinolone-resistance determinant expression. EMBO Rep 10: 929-933.
15. Daniel R, (2004). The soil metagenome-a rich resource for the discovery of novel natural products. Curr Opin Biotechnol 15: 199-204. (Pubitemid 38749041)
16. Devasahayam G, Scheld WM, Hoffman PS, (2010). Newer antibacterial drugs for a new century. Expert Opin Investig Drugs 19: 215-234.
17. Falagas ME, Bliziotis IA, Fragoulis KN, (2007). Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control 35: 106-114. (Pubitemid 46283602)
18. Fernandes P, (2006). Antibacterial discovery and development-the failure of success? Nat Biotechnol 24: 1497-1503. (Pubitemid 44967469)
19. Fleming A, (1929). On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B.influenza. Br J Exp Path 10: 226-236.
20. Flores-Villasenor H, Canizalez-Roman A, Reyes-Lopez M, Nazmi K, de la Garza M, Zazueta-Beltran J, et al,. (2010). Bactericidal effect of bovine lactoferrin, Lfcin, Lfampin and Lfchimera on antibiotic-resistant Staphylococcus aureus and Escherichia coli. Biometals 23: 569-578.
21. Gillings M, Boucher Y, Labbate M, Holmes A, Krishnan S, Holley M, et al,. (2008). The evolution of class 1 integrons and the rise of antibiotic resistance. J Bacteriol 190: 5095-5100. (Pubitemid 351991077)
22. Hair PI, Kean SJ, (2007). Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 67: 1483-1512. (Pubitemid 47028521)
23. House of Lords (1998). Inquiry into antimicrobial resistance. Commun Dis Rep CRD Wkly 24: 8.
24. Hu Y, Shamaei-Tousi A, Liu Y, Coates A, (2010). A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections. PLoS ONE 5: e11818.
25. Hurdle JG, O'Neill AJ, Chopra I, Lee RE, (2011). Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 9: 62-75.
26. IDSA (2010). ID Physicians call for 10 new antibiotics by 2020. Available at (accessed 19 February 2010).
27. IPCC (2007). Climate change 2007: synthesis report. Contribution of working groups I, II and III to the fourth assessment report of the intergovernmental panel on clinate change. In:, Pachauri RK, Reisinger A, (eds). Core Writing Team. IPCC: Geneva, p. 104.
28. Klein E, Smith DL, Laxminarayan R, (2007). Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13: 1840-1846. (Pubitemid 350248484)
29. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al,. (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological and epidemiological study. Lancet Infect Dis 10: 597-602.
30. Lambert PA, (2005). Bacterial resistance to antibiotics: modified target sites. Adv Drug Deliv Rev 57: 1471-1485. (Pubitemid 40984602)
31. Levy SB, Marshall B, (2004). Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10: S122-S129. (Pubitemid 40018235)
32. Lopez AD, Mathers CD, (2006). Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol 100: 481-499. (Pubitemid 47050869)
33. Mitchison DA, (2005). The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 171: 699-706. (Pubitemid 40471139)
34. Mitscher LA, Drake S, Gollapudi SR, Okwute SK, (1987). A modern look at folkloric use of anti-infective agents. J Nat Prod 50: 1025-1040. (Pubitemid 18030551)
35. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2007). Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40. (Pubitemid 46020284)
36. du Plessis M, von Gottberg A, Cohen C, de Gouveia L, Klugman KP, (2008). Neisseria meningitidis intermediately resistant to penicillin and causing invasive disease in South Africa in 2001 to 2005. J Clin Microbiol 46: 3208-3214.
37. Powers JH, (2004). Antimicrobial drug development-the past, the present, and the future. Clin Microbiol Infect 4: 23-31.
38. Rice LB, (2010). Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 1: S7-S10.
39. Riedlinger J, Reicke A, Zahner H, Krismer B, Bull AT, Maldonado LA, et al,. (2004). Abyssomicins, inhibitors of the para-aminobenzoic acid pathway produced by the marin Verrucosispora strain AB- 18-032. J Antibiot (Tokyo) 57: 271-279. (Pubitemid 38594465)
40. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM, (2006). Induction to daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50: 1581-1585.
41. Singh SB, Barrett JF, (2006). Empirical antibacterial drug discovery-foundation in natural products. Biochem Pharmacol 30: 1996-1015.
42. So AD, Gupta N, Cars O, (2010). Tackling antibiotic resistance. BMJ Editorial 340: c2071.
43. Soulsby L, (2008). The 2008 Garrod Lecture: antimicrobial resistance-animals and the environment. J Antimicrob Chemother 62: 229-233.
44. Tenover FC, (2006). Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control 34: S3-10, S64- 73.
45. Walkey AJ, O'Donnell MR, Wiener RS, (2010). Linezolid versus glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 10: 1556.
46. Wang Y, Hong J, Liu X, Yang H, Liu R, Wu J, et al,. (2008). Snake cathelicidin from Bungarus fasciatus is a potent peptide antibiotics. PLoS ONE B3: e3217.
47. Watson R, (2008). Multidrug resistance responsible for half of deaths from healthcare associated infections in Europe. BMJ 336: 1266.
48. Zappia G, Menendez P, Monache GD, Misiti D, Nevola L, Botta B, (2007). The contribution of oxazolidinone frame to the biological activity of pharmaceutical drugs and nature products. Mini Rev Med Chem 7: 389-409. (Pubitemid 46681762)
49. Zhanel GG, Trapp S, Gin AS, DeCorby M, Lagace-Wiens PR, Rubinstein E, et al,. (2008). Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther 6: 67-81. (Pubitemid 351372579)